OncoMatch/Clinical Trials/NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Is NCT06615479 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for relapsed or refractory multiple myeloma (rrmm).
Treatment: BMS-986393 · Cyclophosphamide · Fludarabine · Daratumumab · Pomalidomide · Dexamethasone · Carfilzomib — The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: lenalidomide (lenalidomide)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- UCLA Hematology/Oncology - Santa Monica · Los Angeles, California
- Local Institution - 0050 · Orange, California
- Local Institution - 0223 · Washington D.C., District of Columbia
- Baptist MD Anderson Cancer Center · Jacksonville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06615479 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received lenalidomide.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages